This post is from a suggested group
Addressing Manufacturing Scalability, Purity Challenges, and Cost Efficiency in Oligonucleotide Pool Production to Support the UK’s RNA Therapeutics Pipeline
The UK Oligonucleotide Pool Market faces significant technical and economic challenges, particularly concerning manufacturing scalability, ensuring high product purity, and optimizing cost efficiency, all of which are critical factors for sustaining the nation's burgeoning RNA therapeutics and precision medicine pipeline. Oligonucleotide synthesis, especially for highly complex pools, is an inherently iterative chemical process where each nucleotide addition step carries a small but cumulative risk of error, resulting in a final product containing full-length desired sequences mixed with truncated or error-containing impurities. Maintaining a high percentage of full-length oligo fidelity is technically challenging at high-throughput scale and drives up manufacturing costs due to the need for rigorous purification and quality control steps. This purity challenge is magnified when oligos are intended for clinical applications, where regulatory standards are extremely stringent and necessitate…